Galunisertib

Drug Profile

Galunisertib

Alternative Names: LY-2157299

Latest Information Update: 23 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Developer AstraZeneca; Eli Lilly; National Cancer Institute (USA); Vanderbilt-Ingram Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Pyrazoles; Pyridines; Pyrroles; Quinolines; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myelodysplastic syndromes
  • Phase II Breast cancer; Glioblastoma; Hepatocellular carcinoma; Pancreatic cancer; Rectal cancer
  • Phase I/II Glioma; Non-small cell lung cancer
  • Phase I Cancer; Solid tumours

Most Recent Events

  • 05 Jul 2017 University of Oklahoma and Eli Lilly plan a phase I trial for Ovarian cancer and Uterine cancer (Newly diagnosed, Combination therapy, Recurrent) (NCT03206177)
  • 02 Jun 2017 Adverse events and efficacy data from a phase II trial in Hepatocellular carcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 20 Mar 2017 University of Pennsylvania plans a phase I trial for Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater, Inoperable/unresectable) in USA (NCT03081377)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top